Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

April 12, 2001 12 April, 2001

Pheromone Sciences Corp. Receives Final Clearance on Prospectus

Pheromone Sciences Corp. (CDNX:PHS) today announced that it has received final clearance of its prospectus relating to the $2.0 million special warrant private placement completed in late February.

Under the terms of the placement each special warrant of the Company will be converted, at no additional consideration, into one common share and one- half of a warrant. Each whole warrant will entitle the holder to purchase one common share of the Company at an exercise price of $1.25 per share until February 23, 2002.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.